(Q36409214)

14 August 2017

1 reference

title

Integrins: molecular targets in cancer therapy (English)

1 reference

14 August 2017

Gordon C Tucker

1

1 reference

14 August 2017

1 March 2006

1 reference

14 August 2017

Current Oncology Reports

1 reference

14 August 2017

8

1 reference

14 August 2017

2

1 reference

14 August 2017

96-103

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-006-0043-3

14 August 2017

0 references

cites work

RGD peptides and monoclonal antibodies, antagonists of alpha(v)-integrin, enter the cells by independent endocytic pathways.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-006-0043-3

Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases

21 January 2018

1 reference

12 December 2020

Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3.

1 reference

12 December 2020

Role of integrins in cell invasion and migration

1 reference

12 December 2020

Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion

1 reference

12 December 2020

Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications

1 reference

12 December 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

12 December 2020

Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases.

1 reference

12 December 2020

Integrin adhesion receptors in tumor metastasis

1 reference

12 December 2020

Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD

1 reference

12 December 2020

Integrins: roles in cancer development and as treatment targets

1 reference

12 December 2020

Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin

1 reference

12 December 2020

1 reference

12 December 2020

GPIIb/IIIa antagonists and other anti-integrins

1 reference

12 December 2020

Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone

1 reference

12 December 2020

alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin.

1 reference

12 December 2020

Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts

1 reference

12 December 2020

Pilot study of vitaxin--an angiogenesis inhibitor-in patients with advanced leiomyosarcomas

1 reference

12 December 2020

Endogenous angiogenesis inhibitors

1 reference

12 December 2020

Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma.

1 reference

12 December 2020

Integrins in angiogenesis: multitalented molecules in a balancing act.

1 reference

12 December 2020

Integrins: bidirectional, allosteric signaling machines

1 reference

12 December 2020

Endogenous inhibitors of angiogenesis.

1 reference

12 December 2020

Integrins as a distinct subtype of dependence receptors

1 reference

12 December 2020

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

1 reference

12 December 2020

Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography

1 reference

12 December 2020

Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice

1 reference

12 December 2020

Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist

1 reference

12 December 2020

A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis

1 reference

12 December 2020

A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer

1 reference

12 December 2020

Tumor regression by targeted gene delivery to the neovasculature

1 reference

12 December 2020

Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247.

1 reference

12 December 2020

Integrins and angiogenesis

1 reference

12 December 2020

Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti-alphav integrin monoclonal antibody, despite widespread tissue binding

1 reference

12 December 2020

Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins

1 reference

12 December 2020

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

1 reference

12 December 2020

Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences.

1 reference

12 December 2020

An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model: possible value of integrin alpha2 on platelets as a biological marker

1 reference

12 December 2020

CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo

1 reference

12 December 2020

Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium

1 reference

12 December 2020

Clinical trials referral resource. Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent.

1 reference

12 December 2020

Vitaxin applied molecular evolution.

1 reference

12 December 2020

10.1007/S11912-006-0043-3

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16507218